Clinical research continues to advance across oncology, cardiovascular disease, and cell therapy innovation. Recent developments include the launch of a precision-focused AML trial, dosing of the first patient in a Phase 2 ischemia study, and regulatory clearance for a novel T-cell therapy trial in cervical cancer. These milestones highlight how emerging therapies are progressing through early- and mid-stage clinical development.
Recent updates reported by Clinical Trial Vanguard provide insight into how these trials may influence future treatment strategies.
SELLAS Launches Pioneering AML Trial
SELLAS Life Sciences has enrolled the first patient in a randomized Phase 2 study evaluating its CDK9 inhibitor SLS009 in newly diagnosed acute myeloid leukemia (AML). The trial focuses on patients who are less likely to respond to standard venetoclax-based regimens, using biomarker-driven selection to enrich the study population and improve potential treatment response.
More information is available in Sellas Launches Pioneering AML Trial, Enrolls First Patient.
Aplagon Doses First Patient in Phase 2a Ischemia Trial
Aplagon has dosed the first patient in its Phase 2a HEALING trial evaluating APAC for chronic limb-threatening ischemia caused by peripheral arterial occlusive disease. The study will enroll up to 42 patients and aims to assess safety, biomarker activity, and early efficacy signals in individuals with severe vascular disease.
Further details can be found in Aplagon Announces Dosing in Phase 2a Ischemia Trial.
Cbio Receives Clearance for T-Cell Therapy Trial in Cervical Cancer
Advancements are also emerging in cellular immunotherapy. Cbio has received regulatory clearance to initiate a first-in-human Phase I/IIa study of its T-cell therapy candidate, novoleucel, for patients with persistent or recurrent cervical cancer who have progressed after platinum chemotherapy and checkpoint inhibitors.
Learn more in c-bio Cleared for T-Cell Therapy Trial in Cervical Cancer.
Key Trends in Current Clinical Development
These updates reflect several trends shaping the clinical trial ecosystem:
- Precision-driven oncology trials targeting resistant patient populations
- Novel therapies addressing vascular complications and ischemic disease
- Continued expansion of cell-based immunotherapies for difficult-to-treat cancers
Monitoring these developments provides valuable insight into how clinical innovation continues to progress across multiple therapeutic areas.